Literature DB >> 8205526

Loss of heterozygosity for 10q22-10qter in malignant melanoma progression.

R A Herbst1, J Weiss, A Ehnis, W K Cavenee, K C Arden.   

Abstract

Karyotypic and molecular data indicate that genetic events involving the chromosome region 10q22-10qter may be related to tumorigenesis in malignant melanoma. To test this we analyzed 10 polymorphic microsatellite repeats in the region 10q22-qter, using a polymerase chain reaction-based assay for loss of heterozygosity and DNA isolated from normal and tumor tissue from 26 individuals with malignant melanoma. The samples included 19 paired normal and malignant tissues representing various stages of melanoma as well as 7 cases in which samples from at least 2 different points in time during tumor progression were available. Our findings indicate that loss of heterozygosity of 10q22-10qter is a frequent event, that the observed loss of heterozygosity does not result from whole chromosome loss, and that it is associated with tumor progression. Finally, the appearance of new alleles in two of the tumors may indicate the involvement of DNA replication errors in melanoma analogous to such events in other tumor types.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8205526

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

3.  Unfolding the mutational landscape of human melanoma.

Authors:  Diwakar Davar; Yan Lin; John M Kirkwood
Journal:  J Invest Dermatol       Date:  2015-03       Impact factor: 8.551

4.  Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q.

Authors:  R Albarosa; B M Colombo; L Roz; I Magnani; B Pollo; N Cirenei; C Giani; A M Conti; S DiDonato; G Finocchiaro
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

Review 5.  Liquid Biopsies for Assessing Metastatic Melanoma Progression.

Authors:  Kelly Huynh; Dave S B Hoon
Journal:  Crit Rev Oncog       Date:  2016

Review 6.  Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

Authors:  Nicole Kounalakis; James S Goydos
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

7.  Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.

Authors:  Zorica Milosevic; Nikola Tanic; Jasna Bankovic; Tijana Stankovic; Marko Buta; Dragana Lavrnic; Zorka Milovanovic; Gordana Pupic; Sonja Stojkovic; Vedrana Milinkovic; Yasuhiro Ito; Radan Dzodic
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

8.  AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.

Authors:  Qiang Zuo; Jing Liu; Liping Huang; Yifei Qin; Teresa Hawley; Claire Seo; Glenn Merlino; Yanlin Yu
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

9.  Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.

Authors:  Bret Taback; Steven J O'Day; Peter D Boasberg; Sherry Shu; Patricia Fournier; Robert Elashoff; He-Jing Wang; Dave S B Hoon
Journal:  J Natl Cancer Inst       Date:  2004-01-21       Impact factor: 13.506

10.  In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma.

Authors:  G P Robertson; F B Furnari; M E Miele; M J Glendening; D R Welch; J W Fountain; T G Lugo; H J Huang; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.